Kornimate/medical-research-clean huggingface dataset:
the microbial impact on intestinal fibrosis and the associated immune microenvironment in crohn's disease

Conditions: Crohn Disease (CD)

Summary: the goal of this study is to find out if there is a direct connection between an imbalance of gut bacteria and the development of scar tissue in the gut by identifying important bacterial proteins found in scarred gut tissue. our aim is to identify which types of cells and biological processes are affected by these bacterial proteins in people with crohn's disease. we will also study how these bacterial proteins cause changes in 3d models of gut fibrosis.

more than 50% of cd patients develop a penetrating disease or stenosis due to fibrostenosis, which in most cases requires surgery, as no effective therapies have yet been found. the disease leads to both structural and functional alterations of the intestinal mucosa. although the functional alteration of the mucosa is mainly caused by the continuous tissue damage that occurs during the chronic inflammation associated with cd, recent studies have suggested that the fibrosis associated with cd may be driven by triggering factors independent of inflammation, such as dysbiosis of the microbiota. our proposal aims to establish the causal link between gut dysbiosis and fibrosis by studying the role of key bacterial proteins present in fibrotic gut tissue. this project will ultimately offer new molecular targets for the development of possible tailor-made antifibrotic treatments, with likely benefits for healthcare, as it will facilitate the management of severe cd, avoiding surgery and reducing ssn costs.

Eligibility criteria:
inclusion criteria: * adult patients ≥18 and \<70 years * patients able to autonomously sign the informed consent * non pregnant or breastfeeding patients * for cd patients: cd patients with established diagnosis and additionally classified according to 3 stages: b1 (more inflammatory, non-stricturing), b2 (stricturing, non-penetrating) and b3 (stricturing and penetrating). patients will be stratified on the basis of ct, mri or ultrasound analysis (stratification already known before surgery) * for non-ibd patients: patients with other pathologies but not affected by ibd according to the previously reported clinical and endoscopic evaluation criteria (ex. diverticulitis) exclusion criteria: * patients \ 70 years * pregnant or breastfeeding patients * for cd patients: subjects with cd who do not meet evaluation criteria described above * for non-ibd patients: patients undergoing anti-inflammatory and/or immunosuppressive treatments for ibd-related diseases

Keywords: crohn disease fibrosis dysbiosis microbiota fibrostenosis
study to assess safety and impact of selg1 with or without hydroxyurea therapy in sickle cell disease patients with pain crises

Conditions: Sickle Cell Disease

Summary: the purpose of this study was to determine whether the investigational drug selg1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain crises. selg1 prevents various cells in the bloodstream from sticking together. by stopping these cell-cell interactions, selg1 may prevent small blood vessels from becoming blocked and therefore reduce the occurrence and severity of pain crises. other effects of selg1 was evaluated, as well as the safety of the drug and how long it stayed in the blood stream. funding source - fda office of orphan products development (oopd)


Eligibility criteria:
key inclusion criteria: * sickle cell disease (hbss, hbsc, hbsβ⁰-thalassemia, or hbsβ⁺-thalassemia) * if receiving hydroxyurea or erythropoietin, treatment must have been prescribed for at least 6 months, with the dose stable for at least 3 months * between 2 and 10 sickle cell-related pain crises in the past 12 months key exclusion criteria: * on a chronic transfusion program or planning on exchange transfusion during the study * hemoglobin \<4.0 g/dl * planned initiation, termination, or dose alteration of hydroxyurea during the study * receiving chronic anticoagulation therapy (e.g. warfarin, heparin) other than aspirin

Keywords: selg1 p-selectin monoclonal antibody sickle cell disease sickle cell anemia sickle cell pain crisis pain crises vasoocclusion vaso-occlusion priapism hepatic sequestration splenic sequestration chest syndrome scd
factors influencing the 3-year recurrence of liver carcinoma after surgery

Conditions: Liver Cancer; Recurrence

Summary: objective: 1. to study the factors that influence the 3- year recurrence of liver carcinoma after surgery 2. to study the related factors affecting recurrence of liver carcinoma after surgery

liver carcinoma including 80% hepatocellular carcinoma (hcc) and 20% cholangiocarcinoma (cca) becomes the leading causes of death in east and south-east asia. though hepatectomy is the treatment of choice for early stage cancer, the recurrence has been reported as 30%, 62% and 79% in 1st, 3rd and 5th year respectively. chulabhorn hospital, a cancer institute established in 2011, has been performing a 3-years retrospective study on the influencing factors and its correlation to liver carcinoma after surgery.

Eligibility criteria:
inclusion criteria: * all patients underwent liver resection for hepatiocellular carcinoma and cholangiocarcinoma respectively including having pathology results between february 2010 to december 2013. data was received from cholabhron hospital's patient database. exclusion criteria: * all patients having no pathology results were not included. * all patients having no show for follow up recording were excluded.

Keywords: hepatocellular carcinoma cholangiocarcinoma recurrence
the effect of use of vit d and probiotic as a supplementaition in the treatment of bronchial asthma in patient aged 6 to 50 year and its effect in decrasing excerbation.

Conditions: Bronchial Asthma

Summary: the study of the effect of vit d and probiotic as suprplementaion in the treatment of patient with bonchial asthma and its effect in decreasing number of excerbation

the study of the effect of vit d and probiotic as suprplementaion in the treatment of patient with bonchial asthma and its effect in decreasing number of excerbation

Eligibility criteria:
inclusion criteria: patient wih bronchial asthma aged 6 to50years - exclusion criteria: other comorbities -
post-procedure antibiotic prophylaxis for cardiac electrical device implantation: abxfree study

Conditions: Post Procedural Infection; Pacemaker Electrode Infection; Antibiotics; Implantable Defibrillator User

Summary: this study is a multi-center open-label randomized study, and we sought to investigate the redundancy of post-procedural prophylactic antibiotics in cardiac implantable electronic device implantation. there are 2 arms in this study. one arm will receive pre-procedural intravenous antibiotics only. the other arm will receive both pre-procedural intravenous antibiotics and post-procedural 3-day oral antibiotics.

there is general agreement on the benefits of preoperative prophylactic antibiotics which had been documented in previous studies. concerns of bacterial resistance and unnecessary cost, our prospective observational case-control study had suggested the redundancy of post-procedural antibiotics. in this well-designed study, we sought to investigate the efficacy of post-procedural antibiotics and confirm the hypothesis.

Eligibility criteria:
inclusion criteria: * eligible for permanent pacemaker or implantable cardioverter defibrillator implantation according to current guidelines exclusion criteria: * hospitalization for more than 7 days * end stage renal disease with hemodialysis or peritonealysis * patients receive cardiac resynchronization therapy, his-bundle pacemaker, leadless pacemaker, or sub-cutaneous implantable cardioverter defibrillator

Keywords: prophylactic antibiotics cardiac implantable electronic device infection
tolerability of bimatoprost 0.01% vs latanoprost eye drops

Conditions: Glaucoma

Summary: this study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

patients enrolled in this study completed a validated survey instrument (comtol) examining tolerability of topically applied ophthalmic medications that they are already taking in their regular course of care for glaucoma. the purpose of the study is to determine whether side effects and symptoms of the drugs already being taken cause problems with activities of daily living.

Eligibility criteria:
inclusion criteria: * patients with glaucoma taking either bimatoprost or latanoprost exclusion criteria: * patients taking other medication or with other causes for ocular surface symptoms

Keywords: glaucoma bimatoprost latanoprost tolerability
changes in eye pressure and anterior chamber depth with oral endothelin antagonist therapy

Conditions: Glaucoma; Pulmonary Hypertension

Summary: there is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. pulmonary hypertension (ph)is a disease characterized by low oxygen levels in the blood and altered blood circulation. the decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(nfl)in the retina and the resulting visual field compromise. this situation is characteristic of glaucoma. the ability to identify nfl thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss. we hypothesize that the rate of structural damage to the nfl, a feature of glaucoma, is higher in patients with ph than expected in healthy populations lacking this disease.


Eligibility criteria:
inclusion criteria: * diagnosed with pulmonary hypertension * between the ages of 18 and 80 years * ability to undergo the various ocular exams. exclusion criteria: * patients with other diseases that could affect the nerve fiber layer * special populations; ie children, pregnancy, lactating females, prisoners
effectiveness of community-based physiotherapy versus general practice

Conditions: Chronic Disorders

Summary: summary: (objectives and methodology of the project) aim: to evaluate the clinical effectiveness of community physiotherapy intervention on chronic diseases (heart disease, chronic obstructive pulmonary disease, back pain, mechanical neck pain, fibromyalgia, osteoarthritis lower limbs, neurological and cancer survivors) and a group of healthy patients cardiovascular risk factors. design: randomized, controlled, prospective study. subjects of study: patients with chronic disease go to the local sports torremolinos center intervention: establishment of a control group that give you some advice education care (brief advice) and a group common experimental multimodal program of 12 weeks therapeutic exercise with health education (brief advice). it will follow up complete with ratings pre and post intervention to both groups and follow up at 6 and 12 months for long-term effect through specific questionnaires for each subgroup chronic disease and pain score (visual scale analog), quality of life (euroqol-5d) and state health general (short-form 12, sf-12) variables: the intervention physical therapy community. result: specific questionnaires for each subgroup, pain (visual analogue scale), quality of life (euroqol) and general health status (sf-12). data analysis: descriptive statistics, measuring central tendency and dispersion of the variables study. inferential statistics will be made between intervention of key variables and outcome (chi square, student t, anova, mann-whitney, wilcoxon, by type and normal variables). likewise, establish measures of effect size in main outcome variables, by reduction relative risk, absolute risk and odds ratio with their respective confidence intervals.


Eligibility criteria:
inclusion criteria: * the inclusion criteria will be severe cuts of the disease based on functionality and not the dysfunction indicates the severity level higher 20% of the specific questionnaire for each subgroup exclusion criteria: * common exclusion criteria for subgroups: "rejection of the patient to take part in the survey * processes of infectious, neoplastic, metastasis, osteoporosis, inflammatory arthritis or fractures "cognitive impairment of any etiology presence of unstable angina, arrhythmia, unstable, failure of cardiac valvular "severe hypertension (systolic\> 200 or diastolic\> 120) * depressed systolic function at rest (ef less than 50%) * evidence of exercise-induced ischemia * evidence of exercise-induced arrhythmias. * stenotic coronary lesions greater than 50%. exercise intolerance, or physical activity any cause.

Keywords: primary care physical and aquatic exercises promotion physical activity chronic disorders
restructuring body experience in anorexia nervosa: virtual reality functionality-focused mirror exposure

Conditions: Anorexia Nervosa

Summary: background: body image disturbance remains a core therapeutic challenge in anorexia nervosa (an) treatment, necessitating innovative intervention approaches. this study protocol describes a randomized controlled trial investigating virtual reality functionality-focused mirror exposure (vr-fme), a novel intervention targeting the perceptual, affective, and cognitive dimensions of body image disturbance in an patients. methods: this single-blind, parallel-group randomized controlled trial will evaluate the efficacy of vr-fme as an adjunct to treatment as usual (tau). participants with an will be randomly allocated to receive either vr-fme combined with tau or tau alone. the intervention specifically addresses altered body image through immersive virtual reality technology, providing controlled exposure and cognitive restructuring opportunities. primary outcome: the primary outcome measure will assess changes in body image disturbance severity and core eating disorder symptomatology. we hypothesize that the integration of vr-fme with tau will demonstrate superior therapeutic outcomes compared to tau alone. significance: this protocol represents an innovative approach to addressing body image disturbance in an, potentially enhancing current therapeutic strategies through the integration of immersive virtual reality technology. the findings will contribute to the evolving landscape of technology-enhanced interventions for eating disorders.


Eligibility criteria:
inclusion criteria: * age: between 16-24. * primary diagnosis of anorexia nervosa * bmi \> 14.5 * no current diagnosis or previous diagnosis for neurological disorders * females * fluency in italian * ability to provide informed consent (and parental consent for minors) exclusion criteria: * anorexia nervosa is not a primary diagnosis * age \< 16 * bmi \< 14.5 * conditions that could interfere with vr use (e.g., neurological conditions, severe visual impairments, vestibular disorders) * males * substance abuse, active suicidal ideation, severe psychiatric comorbidities * pregrancy * ongoing participation in other clinical trials * inability to commit to the full duration of the study

Keywords: virtual reality multisensory integration anorexia nervosa body image
a phase 2 study to evaluate morf-057 in adults with moderately to severely active crohn's disease

Conditions: Inflammatory Bowel Diseases; Crohn's Disease

Summary: this is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of morf-057 in adult study participants with moderately to severely active crohn's disease (cd).

this is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of induction therapy with 2 active dose regimens of morf-057 versus matching placebo in adult study participants with moderately to severely active cd. after completion of the 14-week induction period, all participants will receive open-label morf-057 during the 38-week maintenance period. all participants who complete the full 52-week treatment period will also have the opportunity to continue treatment in a 52-week maintenance extension.

Eligibility criteria:
key inclusion criteria: * has signs/symptoms of cd for at least 3 months prior to screening * has a cdai score of 220 to 450, with an average daily stool subscore ≥4 points and/or an average daily abdominal pain subscore of ≥2 points * has an ses-cd score of ≥6 (or an ses-cd score of ≥4 if cd is isolated to the ileum) * demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: corticosteroids, immunosuppressants (eg, azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for cd (eg, biologic agents, janus kinase \[jak\] inhibitors, applicable investigational products) * agrees to abide by the study guidelines and requirements * capable of giving signed informed consent key exclusion criteria: * diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or uc, or has clinical findings suggestive of uc * has cd that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement * has had extensive bowel resection (\>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome * is currently receiving total parenteral nutrition, tube feeding, or a formula diet * has positive findings on a subjective neurological screening questionnaire * has a concurrent, clinically significant, serious, unstable comorbidity * previous treatment with vedolizumab or other licensed or investigational integrin inhibitors * is currently participating in any other interventional study or has received any investigational therapy within 30 days * previous exposure to morf-057 and/or a known hypersensitivity to drugs with a similar mechanism to morf-057 * unable to attend study visits or comply with study procedures

Keywords: crohn's disease (cd) inflammatory bowel disease (ibd) a4b7 moderate-to-severe integrin garnet
a phase ii clinical study of lcb01-0371 to evaluate the eba, safety and pk

Conditions: Pulmonary Tuberculosis

Summary: a prospective, randomized, open, active-controlled, interventional, exploratory, phase ii trial of lcb01-0371.

this study is designed to explore antituberculosis of lcb01-0371 through the assess of the early bactericidal activity, safety of administration.

Eligibility criteria:
inclusion criteria: 1. korean who after listening to understand the details about the clinical trial, decided to join in the clinical study, and written consent 2. the age of consent at the time of writing, only men and women under 75 years old over 19 years old 3. the first diagnosis of tuberculosis and have not received tuberculosis treatment for tb patients exclusion criteria: 1. known history of rifampicin or isoniazid resistance 2. serious tb for example tuberculous encephalomeningitis, it is impossible to participate in clinical trials 3. known history of nontuberculous mycobacteria positive 4. other pulmonary disease which is impossible to participate in clinical trial except tb
effectiveness of pelvic floor muscle and abdominal training in women with stress urinary incontinence

Conditions: Stress Urinary Incontinence; Pelvic Floor Muscle Weakness

Summary: the aim of this study was to investigate the effectiveness of pelvic floor muscle and abdominal training in reproductive-age patients with stress urinary incontinence. this prospective randomized controlled design study included 64 female patients aged 18-49 years with stress urinary incontinence. the patients were divided into 2 groups (32 pfmt "pelvic floor muscle training" and 32 pfmt+at "abdominal training") by computer-based randomization. the stress urinary incontinence type was assessed by a stress test, and the pelvic floor muscle strength was measured with a home biofeedback device. voiding functions were assessed by a 3-day voiding diary and uroflowmetric test. the udi-6 scale was used to assess the urinary symptoms, and the iiq-7 scale was used to assess the quality of life. the follow-up measurements of both groups were obtained in the 0th, 4th, and 8th weeks.

the aim of this study was to investigate the effectiveness of pelvic floor muscle and abdominal training in reproductive-age patients with stress urinary incontinence. this prospective randomized controlled design study included 64 female patients aged 18-49 years with stress urinary incontinence. the patients were divided into 2 groups (32 pfmt "pelvic floor muscle training" and 32 pfmt+at "abdominal training") by computer-based randomization. the stress urinary incontinence type was assessed by a stress test, and the pelvic floor muscle strength was measured with a home biofeedback device. voiding functions were assessed by a 3-day voiding diary and uroflowmetric test. the udi-6 scale was used to assess the urinary symptoms, and the iiq-7 scale was used to assess the quality of life. the follow-up measurements of both groups were obtained in the 0th, 4th, and 8th weeks. participation of 29 patients from each group in the study was determined as sufficient to test the two-way hypothesis, with an effect size of 0.75, with an alpha level of 0.05, and with a power of 80%. however, 32 patients from each group were included as a precaution against possible missing data. these women were randomly divided into the pfmt+at (n=32) and pfmt (n=32) groups using a computer based randomization scheme. the data were collected from both groups at the 0th, 4th, and 8th weeks.

Eligibility criteria:
inclusion criteria * 18-49 years * meet the diagnosis of simple female stress urinary incontinence (degree 0 or 1) * volunteer to participate the study exclusion criteria * bmi ≥30 * hysterectomy, urinary incontinence or pelvic floor operations * chronic health problem (cardiovascular, cerebral, diabetes, liver, kidney, psychiatric disease, etc.) * urge urinary incontinence, mixed urinary incontinence, overflow urinary incontinence * sui degree ≥2 * symptomatic urinary tract infection * during pregnancy or lactation period

Keywords: exercise pelvic floor stress urinary incontinence